SCHOLAR ROCK HOLDING CORPORATION Increase (Decrease) in Accounts Receivable
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Increase (Decrease) in Accounts Receivable of -$25.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2022-03-07
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts receivable for the quarter ending 2020-12-31 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts receivable for the quarter ending 2020-09-30 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts receivable for the quarter ending 2020-06-30 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts receivable for the quarter ending 2020-03-31 was -$25.00M.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts receivable for fiscal 2020 was -$25.00M, a 200.00% decline from fiscal 2019.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts receivable for fiscal 2019 was $25.00M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $0.00 derived: sum of 2 quarters · filed 2022-03-07 | $0.00 derived: sum of 3 quarters · filed 2022-03-07 | -$25.00M 10-K · filed 2022-03-07 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | -$25.00M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$25.00M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$25.00M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $25.00M 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |